We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00192829
Recruitment Status : Unknown
Verified March 2007 by Rambam Health Care Campus.
Recruitment status was:  Recruiting
First Posted : September 19, 2005
Last Update Posted : April 11, 2007
Sponsor:
Information provided by:

September 13, 2005
September 19, 2005
April 11, 2007
June 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00192829 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma
Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma
The association between cancer and thrombosis is well known and the occurrence of thrombotic complications is commonly associated with poor prognosis. The aim os this study is to determine the possible value of hypercoagulable parameters as prognostic parameters in advanced non-small cell lung carcinoma (NSCLC).
Not Provided
Observational
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
  • Non-Small Cell Lung Carcinoma
  • Venous Thromboembolism
Procedure: Blood sample withdrawal
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
100
Not Provided
Not Provided

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of NSCLC.
  • normal serum bilirubin
  • informed concent to participate in the study

Exclusion Criteria:

  • anticoagulant therapy
  • infectious disease
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
 
NCT00192829
Thrombosis and cancer.CTIL
Not Provided
Not Provided
Not Provided
Not Provided
Rambam Health Care Campus
Not Provided
Principal Investigator: Galit Sarig, Ph.D Rambam Health Care Campus
Rambam Health Care Campus
March 2007